Clinical Trials Browser

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myelodysplastic Syndromes, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

NCT02922543 2022-06-14

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Completed

361 enrolled

Classical hematologyOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

Clinical Trials

PC001- A Study to Evaluate the Usability of PointCheck

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

ADVANCE

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Efficacy and Safety Study With MYL-1401H and Neulasta

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

PLIANT

A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

PROTECT2

Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

PROTECT-1

Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)

Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)

Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis

Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers

Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers

Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia

PIONEER

Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients

A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

A Study of Empirical Antifungal Therapy With Itraconazole

A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Treatment for Subjects With Non-Hodgkin's Lymphoma

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients

Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)